Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.
Dynamic prediction
Landmark analysis
Prognostic nomogram
Sarcoma
Soft tissue sarcoma: Survivors
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
14
09
2019
revised:
05
11
2019
accepted:
12
11
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
epublish
Résumé
Prognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop and externally validate a dynamic prognostic nomogram for overall survival in eSTS survivors for use during follow-up. All primary eSTS patients operated with curative intent between 1994 and 2013 at three European and one Canadian sarcoma centers formed the development cohort. Patients with Fédération Française des Centres de Lutte Contre le Cancer (FNCLCC) grade II and grade III eSTS operated between 2000 and 2016 at seven other European reference centers formed the external validation cohort. We used a landmark analysis approach and a multivariable Cox model to create a dynamic nomogram; the prediction window was fixed at five years. A backward procedure based on the Akaike Information Criterion was adopted for variable selection. We tested the nomogram performance in terms of calibration and discrimination. The development and validation cohorts included 3740 and 893 patients, respectively. The variables selected applying the backward procedure were patient's age, tumor size and its interaction with landmark time, tumor FNCLCC grade and its interaction with landmark time, histology, and both local recurrence and distant metastasis (as first event) indicator variables. The nomogram showed good calibration and discrimination. Harrell C indexes at different landmark times were between 0.776 (0.761-0.790) and 0.845 (0.823-0.862) in the development series and between 0.675 (0.643-0.704) and 0.810 (0.775-0.844) in the validation series. A new dynamic nomogram is available to predict 5-year overall survival at different times during the first three years of follow-up in patients operated for primary eSTS. This nomogram allows physicians to update the individual survival prediction during follow-up on the basis of baseline variables, time elapsed from surgery and first-event history.
Sections du résumé
BACKGROUND
BACKGROUND
Prognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop and externally validate a dynamic prognostic nomogram for overall survival in eSTS survivors for use during follow-up.
METHODS
METHODS
All primary eSTS patients operated with curative intent between 1994 and 2013 at three European and one Canadian sarcoma centers formed the development cohort. Patients with Fédération Française des Centres de Lutte Contre le Cancer (FNCLCC) grade II and grade III eSTS operated between 2000 and 2016 at seven other European reference centers formed the external validation cohort. We used a landmark analysis approach and a multivariable Cox model to create a dynamic nomogram; the prediction window was fixed at five years. A backward procedure based on the Akaike Information Criterion was adopted for variable selection. We tested the nomogram performance in terms of calibration and discrimination.
FINDINGS
RESULTS
The development and validation cohorts included 3740 and 893 patients, respectively. The variables selected applying the backward procedure were patient's age, tumor size and its interaction with landmark time, tumor FNCLCC grade and its interaction with landmark time, histology, and both local recurrence and distant metastasis (as first event) indicator variables. The nomogram showed good calibration and discrimination. Harrell C indexes at different landmark times were between 0.776 (0.761-0.790) and 0.845 (0.823-0.862) in the development series and between 0.675 (0.643-0.704) and 0.810 (0.775-0.844) in the validation series.
INTERPRETATION
CONCLUSIONS
A new dynamic nomogram is available to predict 5-year overall survival at different times during the first three years of follow-up in patients operated for primary eSTS. This nomogram allows physicians to update the individual survival prediction during follow-up on the basis of baseline variables, time elapsed from surgery and first-event history.
Identifiants
pubmed: 31891146
doi: 10.1016/j.eclinm.2019.11.008
pii: S2589-5370(19)30214-7
pii: 100215
pmc: PMC6933187
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100215Informations de copyright
© 2019 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
None.
Références
BMC Cancer. 2003 May 26;3:17
pubmed: 12769830
Cancer. 2005 Jan 15;103(2):402-8
pubmed: 15578681
Ann Surg. 2010 Mar;251(3):506-11
pubmed: 20130465
Ann Oncol. 2015 Jun;26(6):1254-62
pubmed: 25862439
Clin Orthop Relat Res. 2013 Nov;471(11):3398-404
pubmed: 23821136
Cochrane Database Syst Rev. 2016 May 27;(5):CD001768
pubmed: 27230946
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Cancer. 2011 Mar 1;117(5):1055-60
pubmed: 20960489
Eur J Cancer. 2017 Sep;83:313-323
pubmed: 28797949
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Br J Surg. 2016 Sep;103(10):1259-68
pubmed: 27488593
Psychooncology. 2013 Jan;22(1):1-11
pubmed: 22232030
N Engl J Med. 2012 Mar 1;366(9):780-1
pubmed: 22375967
Cancer. 2012 Jul 1;118(13):3321-9
pubmed: 22246900
J Clin Oncol. 2011 Oct 20;29(30):4029-35
pubmed: 21931025
Surg Oncol. 2018 Dec;27(4):695-701
pubmed: 30449495
Cancer Epidemiol. 2017 Oct;50(Pt A):150-157
pubmed: 28992567
Eur J Cancer. 2019 Mar;109:51-60
pubmed: 30690293
Int J Cancer. 1984 Jan 15;33(1):37-42
pubmed: 6693192
Eur J Cancer. 2018 Dec;105:19-27
pubmed: 30384013
Cancer. 2014 Oct 1;120(19):3003-6
pubmed: 24942887
Clin Sarcoma Res. 2019 Jul 17;9:11
pubmed: 31346406
J Cancer Educ. 2011 Jun;26(2):397-8
pubmed: 20852978
Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):129-134
pubmed: 29476707
Cancer. 2017 Aug 1;123(15):2802-2820
pubmed: 28493287
Eur J Cancer. 2018 Apr;93:28-36
pubmed: 29475197
Ann Surg. 2012 Feb;255(2):343-7
pubmed: 22143203
Cancer. 2000 Jun 15;88(12):2721-30
pubmed: 10870054
Ann Oncol. 2016 Dec;27(12):2283-2288
pubmed: 27733375
Cancer. 2014 Nov 1;120(21):3361-9
pubmed: 25042799